ASX - Delayed Quote AUD

AVITA Medical, Inc. (AVH.AX)

Compare
2.7700
-0.0100
(-0.36%)
As of 1:51:30 PM GMT+11. Market Open.
Loading Chart for AVH.AX
DELL
  • Previous Close 2.7800
  • Open 2.7900
  • Bid 2.7700 x --
  • Ask 2.7800 x --
  • Day's Range 2.7700 - 2.8200
  • 52 Week Range 2.3400 - 5.6200
  • Volume 38,311
  • Avg. Volume 301,008
  • Market Cap (intraday) 363.114M
  • Beta (5Y Monthly) 1.54
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7100
  • Earnings Date Feb 14, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 4.89

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

www.avitamedical.com

207

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AVH.AX

View More

Performance Overview: AVH.AX

Trailing total returns as of 2/13/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

AVH.AX
34.82%
S&P 500
2.90%

1-Year Return

AVH.AX
47.14%
S&P 500
22.18%

3-Year Return

AVH.AX
7.78%
S&P 500
36.96%

5-Year Return

AVH.AX
82.36%
S&P 500
79.37%

Compare To: AVH.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AVH.AX

View More

Valuation Measures

As of 2/12/2025
  • Market Cap

    363.80M

  • Enterprise Value

    365.74M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.73

  • Price/Book (mrq)

    18.69

  • Enterprise Value/Revenue

    3.82

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -95.47%

  • Return on Assets (ttm)

    -45.37%

  • Return on Equity (ttm)

    -152.44%

  • Revenue (ttm)

    60.04M

  • Net Income Avi to Common (ttm)

    -57.32M

  • Diluted EPS (ttm)

    -0.7100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    44.41M

  • Total Debt/Equity (mrq)

    373.16%

  • Levered Free Cash Flow (ttm)

    -33.68M

Research Analysis: AVH.AX

View More

People Also Watch